echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Fast delivery improves activity and durability, and a new generation of ready-to-use CAR-T therapy is granted orphan drug designation by the FDA

    Fast delivery improves activity and durability, and a new generation of ready-to-use CAR-T therapy is granted orphan drug designation by the FDA

    • Last Update: 2022-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎WuXi AppTec Content Team Editor Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T-cell (AlloCAR T) products targeting cancer

    .

    Recently, the company announced that the U.
    S.
    FDA has granted orphan drug designation (ODD) for the investigational CAR-T therapy ALLO-605 for the treatment of multiple myeloma

    .

    ALLO-605, currently in Phase 1 clinical development, is part of Allogene's multi-pronged strategy to target B cell maturation antigen (BCMA)
    .

    BCMA is a ubiquitously expressed antigen on multiple myeloma cells and a proven anticancer target
    .

    It is worth mentioning that ALLO-605 is the first investigational therapy developed by the company's TurboCAR technology platform, which is expected to improve the function of T cells
    .

    Allogene's TurboCAR platform specifically activates signaling of specific cytokines in CAR-T cells
    .

    A variety of cytokines play an important role in stimulating T cell activity and maintaining T cell persistence, but systemic use of cytokines often brings toxic side effects
    .

    By expressing recombinant proteins on the surface of CAR-T cells, the TurboCAR platform activates the cytokine signaling pathway only in CAR-T cells, thereby improving the function of CAR-T therapy without activating host immune cells, possibly avoiding systemic toxicity
    .

    ▲About ALLO-605 (Image source: Allogene’s official website) The preclinical results of ALLO-605 were announced at the American Society of Hematology (ASH) annual meeting in December 2020.
    Preclinical studies show that TurboCAR technology may improve cell therapy colonization and durability sex, delayed T cell exhaustion

    .

    Additionally, the U.
    S.
    FDA granted Fast Track designation to ALLO-605 in the second quarter of 2021 based on the product candidate's potential to address an unmet need in patients who have failed other standard multiple myeloma treatments

    .

    Rafael Amado, MD, executive vice president of research and development and chief medical officer at Allogene, said: "Orphan drug designation marks an important step toward developing an anti-BCMA portfolio for patients with multiple myeloma and providing patients with an allogeneic CAR-T product.
    Step

    .

    " Reference: Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR T Cell Product Candidate, for the Treatment of Multiple Myeloma.
    Retrieved April 27, 2022, from https://ir.
    allogene.
    com /news-releases/news-release-details/allogene-therapeutics-receives-fda-orphan-drug-designation-allo Disclaimer: The WuXi AppTec content team focuses on global biomedical health research progress

    .

    This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
    .

    This article is also not a treatment plan recommendation
    .

    For guidance on treatment options, please visit a regular hospital
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.